


Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update

Juan R. Bustillo, MD



Because of the wide availability of hardware as well as of standardized analytic quantification tools, proton magnetic resonance spectroscopy (^1H -MRS) has become widely used to study psychiatric disorders. ^1H -MRS allows measurement of brain concentrations of more traditional singlet neurometabolites like N-acetylaspartate, choline, and creatine. More recently, quantification of the more complex multiplet spectra for glutamate, glutamine, inositol, and γ -aminobutyric acid have also been implemented. Here we review applications of ^1H -MRS in terms of informing treatment options in schizophrenia, bipolar disorder, and major depressive disorders. We first discuss recent meta-analytic studies reporting the most reliable findings. Then we evaluate the more sparse literature focused on ^1H -MRS-detected neurometabolic effects of various treatment approaches in psychiatric populations. Finally we speculate on future developments that may result in translation of these tools to improve the treatment of psychiatric disorders.

© 2013, AICH

Dialogues Clin Neurosci. 2013;15:329-337.

Keywords: schizophrenia; spectroscopy; NAA; glutamate; glutamine

Author affiliations: Departments of Psychiatry and Neuroscience, University of New Mexico, Albuquerque, New Mexico, USA

Introduction

Technique overview

Proton magnetic resonance spectroscopy (^1H -MRS) uses the same hardware as magnetic resonance imaging (MRI) to measure various metabolites in the brain. With suppression of the large proton signal from water molecules, the intensity of the relaxation signal from protons attached to other brain metabolites of interest can be quantified in the time domain, as free induction decays (FID). These FIDs are usually Fourier transformed to the frequency domain and depicted as spectra. The area under the curve at a particular frequency (usually in parts per million [ppm] to standardize across magnetic field strengths), can then be quantified and usually referenced to an internal standard (like water spectra or another neurometabolite, eg, total creatine).

With traditional clinical 1.5-Tesla (T) scanners the main metabolites of interest include N-acetylaspartate compounds (NAA plus N-acetylaspartate-glutamate, NAAG), choline (Cho) and creatine (Cre). At higher field strengths (3, 4, and 7 T), the more complex overlapping, multiplets corresponding to glutamate (Glu), glutamine (Gln) and myoinositol (Ins), can also be measured. γ -Aminobutyric acid (GABA) as well as glutathione (GSH) can be quantified at the higher field

Address for correspondence: Juan Bustillo, MD, Department of Psychiatry, MSC 095030, 1 University of New Mexico, Albuquerque, NM, 87131, USA (e-mail: jbustillo@salud.unm.edu)

Pharmacology

Selected abbreviations and acronyms

1H-MRS	<i>proton magnetic resonance spectroscopy</i>
Cho	<i>choline</i>
Cre	<i>creatine</i>
GABA	<i>γ-aminobutyric acid</i>
Gln	<i>glutamine</i>
Glu	<i>glutamate</i>
NAA	<i>N-acetylaspartate</i>
TMS	<i>transcranial magnetic stimulation</i>

strengths with special editing techniques. Most studies have used single voxel acquisition (anywhere between 1 to 40 cc per voxel). This is practical for populations where support for regional pathology is strong. Chemical shift imaging (CSI), simultaneously acquires many voxels (20 to 100, usually 1 to 2 cc each) across a slab of tissue, providing better spatial coverage. However, spectral resolution can be compromised due to magnetic field inhomogeneity.

Interpretation of the meaning of differences in levels measured depends on what is known about the physiology of the various neurometabolites. **NAA is the second most concentrated aminoacid in the brain (after glutamate).** NAA is synthesized in neuronal mitochondria and is located almost exclusively in neurons and their processes. Hence, in neurodegenerative and vascular disease NAA is reduced and it is absent from brain tumor tissue. Consequently, NAA is viewed as a marker of neuronal viability. However, NAA clearly is not a neurotransmitter or neuromodulator, and its function remains unclear. It has been hypothesized to serve as an osmolyte and an acetate donor involved in myelinization.

Choline compounds are trimethylamines but are chemically heterogeneous and have a twofold greater concentration in glial compared with neuronal cells. Consistently, the choline signal tends to be increased in neurodegenerative disorders with gliosis and/or increased membrane turnover.

Myoinositol is the most abundant biologically active stereoisomer of inositol in the brain. Myoinositol is a precursor in the phosphatidylinositol second messenger system, and is also a glial marker. In dementia, elevated

Ins, in conjunction with reduced NAA, has been consistently found.

Glutamate is an aminoacid highly concentrated in all cells and involved in multiple metabolic functions. It is the **principal excitatory neurotransmitter** in the central nervous system (CNS). However, **only a minimal proportion of ¹H-MRS-measured glutamate signal comes from the synapses.** Conversely, glutamine is mainly synthesized **in the glia from** synaptic glutamate and has been used as an index of glutamatergic neurotransmission.

GABA is the principal inhibitory neurotransmitter in the CNS. Although technically challenging, its ¹H-MRS measurement can be more easily interpreted than the levels of glutamate or even glutamine. Finally, creatine and phosphocreatine are easily measured and are involved in energy metabolism. Although often used as a reference for other metabolites, interpretation of the meaning of creatine group differences is poorly understood.


Schizophrenia

Disease-related findings

Over the last three decades there have been many ¹H-MRS studies comparing schizophrenic (Sz) and healthy control groups, and these have been summarized in three meta-analyses. Steen et al¹ reported reduced NAA in frontal and medial temporal regions. Kraguljac et al² confirmed NAA reductions in frontal and basal ganglia regions with no evidence of changes in Cho or Cre. **A smaller number of studies have examined Glu, Gln, and Glx.** Marsman et al³ reported increased Gln and Gln/Glu ratio in medial frontal cortex, more apparent earlier than later in the illness. In the last 4 years a few studies have examined GABA in Sz and the results have been inconsistent: two studies found reductions,^{4,5} two elevations,^{6,7} and one no differences.⁸ Finally, one study detected glutathione reductions in frontal cortex as well as in cerebrospinal fluid of drug-free Sz.⁹

This literature confirms that in schizophrenia (mostly chronically treated patients) there are reductions in

Figure 1. (opposite) Single voxel location (2 x 2 x 3 cm) in the anterior dorsal cingulate cortex, shown in sagittal, coronal, and axial planes from MRI (top panel). A spectra, averaged from 196 acquisitions, collected from the above location at 3 Tesla, with a standard point resolved spectroscopic sequence (time to echo = 40 msec, time to repetition = 1500 msec), in about 5 mins. The fitted spectra (red line) has peak areas for glutamine (Gln), glutamate (Glu), N-acetyl-aspartate compounds (NAAc), total-creatine (Cre), myo-inositol (Ins) and choline (Cho) are labeled. Top irregular line represents the residual signal after fitting. Lower continuous line represents the baseline used for fitting with linear combination (LC) model (bottom panel).



Pharmacology

NAA in frontal and basal ganglia regions, consistent with neuronal dysfunction (postmortem literature has consistently failed to find neuronal loss). A more limited literature supports elevations of Gln in medial frontal regions, suggestive of increased glutamatergic neurotransmission.

Treatment-related studies

Treatment studies using 1H-MRS not surprisingly lag in number compared with cross-sectional investigations. Most of them have been naturalistic observations before and after treatment with antipsychotic agents. Theberge et al¹⁰ examined antipsychotic-naïve Sz subjects at baseline, 10, and 30 months following antipsychotic treatment. Baseline thalamic Gln elevations were decreased at 30 months, and correlated with widespread temporal and parietal gray matter reductions. This was interpreted as evidence of glutamate-related disease progression, not as a medication effect (at 10 months, Gln did not change).

Although a few studies have reported increases in NAA with treatment, the majority have failed to do so. Bertolino et al,¹¹ in a retrospective study, reported higher NAA/Cr in the dorsolateral prefrontal cortex in patients while treated with antipsychotic medication compared with when they were medication-free. Fannon et al¹² reported reduced medial temporal NAA/Cr at baseline, which was no longer statistically different from healthy subjects after 3 months of atypical antipsychotic treatment. However, Choe et al¹³ found low frontal NAA/Cr at baseline with no changes after treatment with typical and atypical agents (follow-up 1–6 months). We found frontal and striatal NAA reductions in minimally treated patients that did not change following 9-month randomized treatment with quetiapine or haloperidol.¹⁴ Szulc et al¹⁵ reported no NAA changes following treatment with various antipsychotics. Finally, Theberge et al¹⁰ found no NAA changes following a 30-month treatment.

These clinical studies are generally consistent with largely negative findings in the animal 1H-MRS literature examining antipsychotic exposure in rats. Lindquist et al¹⁶ found no reductions of frontal NAA after 1 week of haloperidol but a reduction with olanzapine. We found no changes in NAA after 6 weeks of clozapine or haloperidol.¹⁷ Additionally, 6 months exposure to haloperidol produced no changes in NAA, Glu, Gln, or

GABA.¹⁸ However, Harte et al¹⁹ did find increased NAA in the rat striatum with long-term haloperidol exposure, consistent with dendritic sprouting. Antipsychotic drugs are known to induce structural volume increases in the human striatum²⁰ and cortical volume reductions,²¹ but no neuronal loss. Hence, the ability to detect changes in neuronal tissue concentration would depend on the spatial resolution of the 1H-MRS technique (currently limited to 1 cc, clearly suboptimal for the 2- to 3-mm thick human cortex) as well as the timing of acquisition.

A recent longitudinal study of antipsychotic-naïve schizophrenia examined Glu and NAA in the caudate before and 4 weeks following treatment with risperidone.²² Baseline Glu elevations normalized with treatment but there were no changes in NAA. However, the Glu normalization did not correlate with symptom improvement. These results are consistent with a dopamine D2 modulation of striatal hypoglutamatergia. Consistently, Goto et al²³ reported similar Glx prefrontal reductions following 6 months of antipsychotic treatment.

Experimental agent studies

Few studies have used 1H-MRS to examine neurochemical effects of **non-dopamine D2 blockers** for potential applications in schizophrenia. Jarkog et al²⁴ recently examined the effect of adjunct **davunetide** (a neurotrophic peptide) for 12 weeks in schizophrenia. Higher-dose davunetide (30 mg/day) resulted in marginal prefrontal NAA and Cho increases, suggesting a neuroprotective effect. However, there were no correlations with symptoms or cognitive measures.

Glycine has been examined for the treatment of negative symptoms, and an 1H-MRS sequence is sensitive enough to detect brain elevations in the context of oral administration in healthy volunteers.²⁵ Future studies may examine the glycine spectra in clinically treated populations. Finally, in a knockout mouse model with reduced glutathione, N-acetyl cysteine administration during gestation was found to revert abnormally elevated prepuberal brain Gln and Gln/Glu.²⁶ **This is somewhat consistent with a study documenting effects of N-acetyl cysteine (NAC) on negative symptoms.**²⁷ However, there have been no reports examining the effects of NAC on 1H-MRS measures in schizophrenia.

Bipolar disorder

Disease-related findings

The Kraguljac et al² meta-analysis reported NAA reductions only in basal ganglia and elevations in dorso lateral prefrontal cortex (however, heterogeneity of studies was high for the latter). There were no differences in Cre or Cho. In another meta-analysis²⁸ Glx was found to be elevated, mainly in the frontal region, regardless of medication or clinical state.²⁹ One study reported reduced occipital GABA.³⁰ These results suggest increased glutamatergic indices in bipolar disorder, without the more widespread neuronal dysfunction (reduced NAA) found in schizophrenia.

Treatment-related studies

Some studies have used ¹H-MRS in bipolar mania to evaluate correlates of treatment with lithium, other mood stabilizers, and antipsychotic agents.

Lithium

Cross-sectional studies suggested that lithium therapy increases NAA^{31,32} in bipolar patients. However, longitudinal human studies^{33,34} as well as a rodent study³⁵ failed to detect NAA changes. Conversely, reductions in Glx have been reported in longitudinal human³³ and rat³⁵ studies with lithium, consistent with an improvement of Glx in bipolar disorder. However, documentation of a relationship between Glx reductions and symptom improvement is lacking. Additionally, lithium induced myo-inositol reductions which did not relate to changes in mood,³⁶ but another longitudinal study found increases in this metabolite.³³ In general, no clear pattern of lithium related ¹H-MRS changes has been documented in clinical populations. However, spectroscopic measurement of brain lithium in treated bipolar subjects does correlate with serum lithium levels.³⁷ This approach may result in a clinical application for lithium MRS in the future.

Other agents

Strawn et al³⁸ studied adolescents in a manic episode before open-label treatment with divalproex and 1 and 4 weeks later. Remitters had lower Glx in the left ventro

lateral prefrontal cortex compared with nonremitters. However, in adult bipolar patients treated with valproic acid, Glx failed to predict response.³³ In rats, sodium valproate did induce reductions in glutamate.³⁵

Depression

Disease-related findings

Two meta-analyses have examined ¹H-MRS neurometabolite findings in major depressive disorder. Yildiz-Yesiloglu and Ankerst³⁹ reported an increase in Cho/Cre ratio in basal ganglia in major depression with no changes in NAA. This was interpreted as increased membrane turnover without evidence of neuronal damage. More recently, Glx was found reduced in the anterior cingulate cortex during a depressive episode.⁴⁰ This suggests that contrary to bipolar mania, glutamatergic metabolism is reduced in a state-dependent relationship in depression. Finally, reduced occipital GABA has been found in MDD.^{41,42}

Treatment-related studies

Since Cho levels tend to be increased in MDD, some studies have examined their relationship to treatment. Charles et al⁴³ reported Cho/Cre reductions with nefazodone treatment. However, Cho increases have been reported in other drug⁴⁴ and transcranial magnetic stimulation (TMS)⁴⁵ studies in treatment responders.

Baseline reductions of Glx would be expected to increase with therapy. Indeed, electroconvulsive therapy (ECT) normalized reduced prefrontal Glx⁴⁶ and successful TMS increased Glu44 in depression. Regarding GABA, baseline occipital reductions increased with serotonin reuptake inhibitors.⁴¹ Similarly, ECT increased GABA⁴² but cognitive behavioral therapy (CBT), failed to do so.⁴⁷

Some studies have examined a neurotrophic effect of various treatments by examining NAA. The results for ECT have been mixed in terms of NAA changes.^{48,49} However, there is a modest but consistent literature suggesting increases in NAA with antidepressant medication.⁵⁰⁻⁵² Finally, new strategies for depression with NMDA blockers have been studied recently and examinations of glutamate metabolism undertaken. Salvatore et al⁵³ found that the pretreatment prefrontal Glx/Glu ratio was negatively correlated with improvement in

Pharmacology

depressive symptoms. However neither GABA nor Glu levels predicted treatment response. Still, the development of NMDA modulators for the treatment of depressive disorders is likely to benefit from the in-vivo examination of glutamate and GABA with ¹H-MRS.

Summary of findings

¹H-MRS has been widely used to study major psychiatric illness, and several findings have been consistently reported. In schizophrenia, prefrontal NAA is reduced and glutamine increased, suggestive of glutamate-related excitotoxicity. In bipolar disorder, there is increased prefrontal glutamatergic metabolism (elevated Glx) perhaps as a trait measure. In major depression, basal ganglia choline is increased, while prefrontal Glx and occipital GABA are reduced and these may represent state abnormalities. Presently, none of these effects are sufficiently sensitive or specific to have any diagnostic implication.

The literature regarding applicability of ¹H-MRS to evaluate effects of treatment is, not surprisingly, more limited. In schizophrenia, NAA reductions are not caused, but also not restored, by antipsychotic agents. However, there is evidence that antipsychotics may reduce elevated glutamatergic indices, especially in the striatum, their primary site of action. In bipolar disorder, the ¹H-MRS correlates of response to lithium and other mood

stabilizers have not been elucidated. However, lithium quantification in brain is possible and may have future clinical applications. Regarding depression, it is encouraging that restoration of reduced glutamate and GABA have been documented with ECT, TMS, and antidepressant medication. Additionally, a small but reliable increase of NAA with medication is consistent with the neurotrophic effects of antidepressant drugs. However, the correlations with symptom improvement for these ¹H-MRS /treatment relationships have been modest at best and no clinical applications are available.

Table I summarizes the strengths and weaknesses of MRS.

Future directions

In terms of technique development there is a need for sequences with broader spatial coverage so that true imaging of multiple metabolites is possible, with enough spatial resolution to allow full integration with other modalities. This would allow, for example, to test whether NAA reductions in white matter in schizophrenia, correspond or not to the well-described reductions in fractional anisotropy (FA), acquired with DTI. Additionally, techniques that reliably block lipid signal contamination, will permit more specific examination of peripheral cortical regions. Improved hardware and shimming techniques may allow measurements in deeper structures,

Strengths

- Accessible: available in most magnetic resonance (MR) centers with clinical scanners
- Safe: no radiation, allows for repeated studies in same individuals
- Transferable: easily transfers to animal models of disease to test mechanistic explanations of descriptive clinical findings
- Specific measurements: of neuroactive metabolites not currently available with radio-labelled PET studies (like γ -aminobutyric acid, glutamate, glutamine, glycine, glutathione)
- Integration with other modalities: easy to acquire in the same session with others (eg, MRI, diffusion tensor imaging, functional MR)

Weaknesses

- Spectral resolution: restricted to a few metabolites, some of doubtful significance
- Partial volume: because cortex macrostructure is in single millimeters and MRS voxels are in tens of millimeters, partial volume effects are significant and must be addressed. Tissue relaxation parameters: these can affect perceived metabolite concentrations and for several metabolites are not well known
- Spatial coverage: limited to single voxel acquisitions for the most potentially meaningful metabolites. Even multivoxel MRS typically includes a only few hundred voxels. Because of spatial coverage and partial volume limitations, actual integration with other imaging modalities is difficult
- Signal to noise: low compared with water-based MR techniques. Effect sizes likely to be very small in psychiatric illnesses, so large samples generally necessary

Table I. Strengths and weaknesses of magnetic resonance spectroscopy.

like the amygdala or hippocampus, which are currently accessible mainly for the singlet peaks easier to measure.

Editing techniques at higher field strength with improved spectral resolution may allow measurement of neuroactive metabolites in smaller, more physiologically plausible regions. Experiments in animals using microscopic and functional tools in addition to descriptive MRS measurements, would greatly advance the interpretation of clinical studies. Finally, in terms of clinical

design, large samples (in the hundreds, like other modalities) of different clinical populations early in the illness, with long-term longitudinal follow-up, will be necessary. With renewed interest in excitatory/inhibitory neurotransmitter systems beyond traditional bioaminergic functions, more sophisticated ¹H-MRS studies of glutamate, glutamine, GABA, and glycine, in the context of various treatment modalities, may translate into clinical applications in psychiatry. □

El empleo de la espectroscopía de resonancia magnética de protón en el tratamiento de los trastornos psiquiátricos: una actualización crítica

La espectroscopía de resonancia magnética de protón (¹H-MRS) ha llegado a emplearse ampliamente en el estudio de los trastornos psiquiátricos. Hay una amplia disponibilidad de equipos como de herramientas estandarizadas de cuantificación analítica. La ¹H-MRS permite la medición de concentraciones cerebrales de neurometabolitos con los singletes más tradicionales como el N-acetilaspártato, la colina y la creatina. Hace poco se ha implementado la cuantificación de espectros múltiples más complejos para el glutamato, la glutamina, el inositol y el ácido gama-amino-butírico. En este artículo se revisan las aplicaciones de la ¹H-MRS en relación con la información que pueda aportar para las alternativas terapéuticas en esquizofrenia, trastorno bipolar y trastornos depresivos mayores. Primero se discuten los estudios de meta-análisis recientes que dan cuenta de los hallazgos más confiables. Luego se evalúa la más amplia y diversa literatura orientada a los efectos neurometabólicos detectados con la ¹H-MRS en varios esquemas terapéuticos en pacientes psiquiátricos. Finalmente se especula acerca de los futuros desarrollos que pueden surgir en la traslación de estas herramientas para mejorar el tratamiento de los trastornos psiquiátricos.

La espectroscopie par résonance magnétique nucléaire protonique dans le traitement des troubles psychiatriques : une revue critique des données récentes

Grâce au grand choix de matériels et d'outils de quantification analytique standardisés, la spectroscopie par résonance magnétique nucléaire protonique (RMN ¹H) est largement utilisée dans l'étude des troubles psychiatriques. Elle permet de mesurer les concentrations cérébrales de métabolites singlets classiques comme le N-acétyl-aspartate, la choline, la créatine auxquels se sont rajoutés plus récemment la quantification des spectres plus complexes de multiplets comme le glutamate, la glutamine, l'inositol et l'acide gamma-aminobutyrique. Nous analysons dans cet article les applications de la RMN ¹H en termes d'information sur les choix thérapeutiques dans la schizophrénie, les troubles bipolaires et la dépression majeure. Nous examinons tout d'abord les récentes métaanalyses rapportant les résultats les plus fiables, puis nous évaluons la littérature plus limitée sur les effets neurométaboliques détectés par RMN ¹H des différents traitements chez des patients psychiatriques. Enfin, nous imaginons le développement à venir de ces outils dans le cadre du traitement des troubles psychiatriques.

REFERENCES

1. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by ¹H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. *Neuropsychopharmacology*. 2005;30:1949-1962.
2. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. *Psychiatry Res*. 2012;203:111-125.
3. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of H-MRS studies. *Schizophr Bull*. 2013;39:120-129.
4. Goto N, Yoshimura R, Moriya J, et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. *Schizophr Res*. 2009;112:192-193.
5. Yoon JH, Maddock RJ, Rokem A, et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. *J Neurosci*. 2010;30:3777-3781.

Pharmacology

6. Ongur D, Prescott AP, McCarthy J, Cohen BM, Renshaw PF. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. *Biol Psychiatry*. 2010;68:667-670.
7. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. *Arch Gen Psychiatry*. 2012;69:449-459.
8. Rowland LM, Kontson K, West J, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. *Schizophr Bull*. In press.
9. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. *Eur J Neurosci*. 2000;12:3721-3728.
10. Theberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. *Br J Psychiatry*. 2007;191:325-334.
11. Bertolino A, Callicott JH, Mattay VS, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. *Biol Psychiatry*. 2001;49:39-46.
12. Fannon D, Simmons A, Tennakoon L, et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naïve patients with schizophrenia. *Biol Psychiatry*. 2003;54:587-598.
13. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. *Invest Radiol*. 1996;31:345-352.
14. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. *Neuropsychopharmacology*. 2008;33:2456-2466.
15. Szulc A, Galinska B, Tarasow E, et al. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. *Pharmacopsychiatry*. 2011;44:148-157.
16. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. *Magn Reson Med*. 2000;43:355-358.
17. Bustillo J, Wolff C, Myers-Gutierrez A, et al. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. *Schizophr Res*. 2004;66:31-39.
18. Bustillo J, Barrow R, Paz R, et al. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. *Neuropsychopharmacology*. 2006;31:751-756.
19. Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. *Schizophr Res*. 2005;75:303-308.
20. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. *Am J Psychiatry*. 1994;151:1430-1436.
21. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Arch Gen Psychiatry*. 2011;68:128-137.
22. de la Fuente-Sandoval C, Léon-Ortiz P, Azcárraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. *JAMA Psychiatry*. In press.
23. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. *Neuropsychiatr Dis Treat*. 2012;8:119-122.
24. Jarskog LF, Dong Z, Kangarlou A, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. *Neuropsychopharmacology*. 2013;38:1245-52.
25. Kaufman MJ, Prescott AP, Ongur D, et al. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. *Psychiatry Res*. 2009;173:143-149.
26. das Neves Duarte JM, Kulak A, Gholam-Razae MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. *Biol Psychiatry*. 2012;71:1006-1014.
27. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. *Biol Psychiatry*. 2008;64:361-368.
28. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. *Bipolar Disord*. 2012;14:478-487.
29. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. *Biol Psychiatry*. 2010;68:785-794.
30. Bhagwagar Z, Wylezinska M, Jezard P, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. *Int J Neuropsychopharmacol*. 2008;11:255-260.
31. Hajek T, Bauer M, Pfennig A, et al. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. *J Psychiatry Neurosci*. 2012;37:185-192.
32. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. *Int Clin Psychopharmacol*. 2003;18:73-79.
33. Friedman SD, Dager SR, Parow A, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. *Biol Psychiatry*. 2004;56:340-348.
34. Brambilla P, Stanley JA, Sassi RB, et al. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. *Neuropsychopharmacology*. 2004;29:1918-1924.
35. O'Donnell T, Rotzinger S, Ulrich M, Hanstock CC, Nakashima TT, Silverstone PH. Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. *Eur Neuropsychopharmacol*. 2003;13:220-227.
36. Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. *Am J Psychiatry*. 1999;156:1902-1908.
37. Lee JH, Adler C, Norris M, et al. 4-T 7Li 3D MR spectroscopy imaging in the brains of bipolar disorder subjects. *Magn Reson Med*. 2012;68:363-368.
38. Strawn JR, Patel NC, Chu WJ, et al. Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study. *J Am Acad Child Adolesc Psychiatry*. 2012;51:642-651.
39. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. *Psychiatry Res*. 2006;147:1-25.
40. Luyckx JJ, Laban KG, van den Heuvel MP, et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of H-MRS findings. *Neurosci Biobehav Rev*. 2012;36:198-205.
41. Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. *Am J Psychiatry*. 2002;159:663-665.
42. Sanacora G, Mason GF, Rothman DL, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. *Am J Psychiatry*. 2003;160:577-579.
43. Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. *Prog Neuropsychopharmacol Biol Psychiatry*. 1994;18:1121-1127.
44. Sonawalla SB, Renshaw PF, Moore CM, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. *Am J Psychiatry*. 1999;156:1638-1640.
45. Luborzewski A, Schubert F, Seifert F, et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. *J Psychiatr Res*. 2007;41:606-615.
46. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfeleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. *Psychol Med*. 2003;33:1277-1284.
47. Sanacora G, Fenton LR, Fasula MK, et al. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. *Biol Psychiatry*. 2006;59:284-286.
48. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfeleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. *Neuropsychopharmacology*. 2003;28:720-725.
49. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA. The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. *Arch Gen Psychiatry*. 2000;57:937-943.

50. Gonul AS, Kitis O, Ozan E, et al. The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006;30:120-125.
51. Block W, Traber F, von Widdern O, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. *Int J Neuropsychopharmacol*. 2009;12:415-422.
52. Taylor MJ, Godlewska BR, Norbury R, Selvaraj S, Near J, Cowen PJ. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. *Int J Neuropsychopharmacol*. 2012;15:1541-1546.
53. Salvatore G, van der Veen JW, Zhang Y, et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. *Int J Neuropsychopharmacol*. 2012;15:1063-1072.